Table 3.

Miscellaneous outcomes reported in the included studies

Study, YearOutcomes AnalyzedResults
Bagnis, 1998 (29)BAP, osteocalcinReduction in osteocalcin but not BAP
Courbebaisse, 2009 (19)UCa/Cr, urinary calcium, eGFRNS change with intervention
Chandra, 2008 (24)BAP, C telopeptide, TRAP 5bNS change with intervention
Dogan, 2008 (25)Albumin, UCa/Cr, BAP, eGFRNS change with intervention
Blair, 2008 (30)Albumin, Hb, eKt/V, nPCR, SF 36Significant improvement in Hb, nPCR
Finn, 2009 (39)Albumin, eGFRNS change with intervention
Jean, 2009 (33)Albumin, Hb, eKt/V, nPCR, ESA requirementNS change with intervention
Lopes, 2009 (20)BAP, urinary calcium, FGF23,Significant reduction in BAP and increase in Urinary calcium
Mathias, 2009 (40)ESA requirementNS change with intervention
Saab, 2007 (34)ESA requirementNS change with intervention
Oksa, 2008 (23)Urinary calciumNS change with intervention
Wissing, 2005 (26)Urinary calciumNS change with intervention
Zisman, 2007 (37)eGFRNS change with intervention
  • BAP, bone alkaline phosphatase; UCa/Cr, urinary calcium-to-creatinine ratio; eGFR, estimated GFR; eKtV, estimated KtV; TRAP 5B, tartarate-resistant acid phosphatase isoform 5 b; Hb, hemoglobin; nPCR, protein catabolic rate; SF 36, Standard Form 36 questionnaire; ESA, erythropoietin stimulating agents; NS, not significant; FGF23, fibroblast growth factor-23.